Lexeo Therapeutics, Inc. Common Stock (LXEO) - Total Liabilities
Based on the latest financial reports, Lexeo Therapeutics, Inc. Common Stock (LXEO) has total liabilities worth $23.01 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Lexeo Therapeutics, Inc. Common Stock cash flow conversion to assess how effectively this company generates cash.
Lexeo Therapeutics, Inc. Common Stock - Total Liabilities Trend (2020–2024)
This chart illustrates how Lexeo Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Lexeo Therapeutics, Inc. Common Stock's assets to evaluate the company's liquid asset resilience ratio.
Lexeo Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Lexeo Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kehua Holdings Co Ltd Class A
SHG:603161
|
China | CN¥1.44 Billion |
|
Fagerhult AB
ST:FAG
|
Sweden | Skr6.56 Billion |
|
Chunbo Co. Ltd
KQ:278280
|
Korea | ₩382.16 Billion |
|
Zhejiang Wanfeng Chemical Co. Ltd. A
SHG:603172
|
China | CN¥391.97 Million |
|
Poongsan Holdi
KO:005810
|
Korea | ₩203.01 Billion |
|
Diplomat Holdings Ltd
TA:DIPL
|
Israel | ILA1.12 Billion |
|
DBV Technologies S.A.
PA:DBV
|
France | €57.64 Million |
|
Advanced Enzyme Technologies Limited
NSE:ADVENZYMES
|
India | Rs1.58 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Lexeo Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Lexeo Therapeutics, Inc. Common Stock.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lexeo Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lexeo Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual total liabilities of Lexeo Therapeutics, Inc. Common Stock from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $30.10 Million | +14.57% |
| 2023-12-31 | $26.27 Million | -87.49% |
| 2022-12-31 | $210.03 Million | +9.13% |
| 2021-12-31 | $192.46 Million | +450.75% |
| 2020-12-31 | $34.95 Million | -- |
About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a… Read more